echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Heji Pharmaceutical - the world's first clinical ITK inhibitor Phase I/Ib trial administered to the first patient in China

    Heji Pharmaceutical - the world's first clinical ITK inhibitor Phase I/Ib trial administered to the first patient in China

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    CPI-818 is a first-in-class, oral inhibitor that potently inhibits ITK kinase.


    Dr.


    Director of the Chinese Society of Clinical Oncology (CSCO) , Secretary General of the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology (CSCO ) , China's leading researcher of the CPI-818-001 clinical trial, and Professor Song Yuqin, Department of Lymphoma, Peking University Cancer Hospital, said : "China is the world's In countries with a large number of T-cell lymphoma patients within the scope, the current five-year survival rate of patients with relapsed/refractory T-cell lymphoma is only 10-30%, which is an urgent clinical need


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.